Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.

Mathurin FumeryAntoine DefranceXavier Roblin Romain AltweggBenedicte CaronXavier HébuterneCarmen StefanescuAntoine MeyerMaria NachuryDavid LaharieStephane NanceyCatherine Le BerreMelanie SerreroSophie GeylCyrielle GilettaPhilippe Ah-SouneNicolas DuveauMathieu UzzanVered AbitbolAmelie BironMy-Linh Tran-MinhThierry PaupardLucine VuittonYasmine ElgharabawyLaurent Peyrin Biroulet

Published in: Alimentary pharmacology & therapeutics (2022)

In a cohort of highly refractory patients with luminal CD and multiple prior drug failures including ustekinumab, risankizumab induction provided a clinical response in about 3 out of 4 patients and steroid-free clinical remission in about half of patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
emergency department
rheumatoid arthritis
patient reported outcomes